KR20170090499A - Ｅｇｆｒ 억제제와 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체의 조합 - Google Patents
Ｅｇｆｒ 억제제와 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체의 조합 Download PDFInfo
- Publication number
- KR20170090499A KR20170090499A KR1020177018885A KR20177018885A KR20170090499A KR 20170090499 A KR20170090499 A KR 20170090499A KR 1020177018885 A KR1020177018885 A KR 1020177018885A KR 20177018885 A KR20177018885 A KR 20177018885A KR 20170090499 A KR20170090499 A KR 20170090499A
- Authority
- KR
- South Korea
- Prior art keywords
- pyrimidin
- methyl
- dihydro
- oxo
- benzyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14004200 | 2014-12-12 | ||
| EP14004200.3 | 2014-12-12 | ||
| PCT/EP2015/002265 WO2016091346A1 (en) | 2014-12-12 | 2015-11-12 | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170090499A true KR20170090499A (ko) | 2017-08-07 |
Family
ID=52133768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177018885A KR20170090499A (ko) | 2014-12-12 | 2015-11-12 | Ｅｇｆｒ 억제제와 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체의 조합 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10532052B2 (ru) |
| EP (1) | EP3229806A1 (ru) |
| JP (1) | JP2017537939A (ru) |
| KR (1) | KR20170090499A (ru) |
| CN (1) | CN106999493A (ru) |
| AU (1) | AU2015360005A1 (ru) |
| BR (1) | BR112017012136A2 (ru) |
| CA (1) | CA2970391A1 (ru) |
| CL (1) | CL2017001478A1 (ru) |
| IL (1) | IL252752A0 (ru) |
| MX (1) | MX2017007372A (ru) |
| PH (1) | PH12017500718A1 (ru) |
| RU (1) | RU2017124612A (ru) |
| SG (1) | SG11201704767YA (ru) |
| UA (1) | UA120108C2 (ru) |
| WO (1) | WO2016091346A1 (ru) |
| ZA (1) | ZA201704654B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3231793T1 (sl) | 2014-12-12 | 2020-07-31 | Japan Tobacco Inc. | Spojine dihidropirimidin-2-ona in njihove medicinske uporabe |
| CN111741947B (zh) | 2018-02-28 | 2024-06-11 | 日本烟草产业株式会社 | 4-甲基二氢嘧啶酮化合物及其药物用途 |
| US11455294B2 (en) * | 2019-10-18 | 2022-09-27 | Sap Se | Information lifecycle management notification framework |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060188498A1 (en) | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| US20090155247A1 (en) | 2005-02-18 | 2009-06-18 | Ashkenazi Avi J | Methods of Using Death Receptor Agonists and EGFR Inhibitors |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| US20110229469A1 (en) * | 2008-10-01 | 2011-09-22 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
| CA2749012C (en) | 2009-01-08 | 2017-01-31 | Merck Patent Gmbh | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof |
| NZ609957A (en) | 2010-11-01 | 2015-08-28 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
| BR112014022789B1 (pt) | 2012-03-15 | 2022-04-19 | Celgene Car Llc | Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo |
| EP2827872A1 (en) | 2012-03-19 | 2015-01-28 | Merck Patent GmbH | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds |
| CN104245701A (zh) * | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
| WO2014056566A1 (en) | 2012-10-11 | 2014-04-17 | Merck Patent Gmbh | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
-
2015
- 2015-11-12 WO PCT/EP2015/002265 patent/WO2016091346A1/en active Application Filing
- 2015-11-12 US US15/534,527 patent/US10532052B2/en not_active Expired - Fee Related
- 2015-11-12 SG SG11201704767YA patent/SG11201704767YA/en unknown
- 2015-11-12 UA UAA201707191A patent/UA120108C2/uk unknown
- 2015-11-12 EP EP15794469.5A patent/EP3229806A1/en not_active Withdrawn
- 2015-11-12 BR BR112017012136-0A patent/BR112017012136A2/pt not_active Application Discontinuation
- 2015-11-12 CA CA2970391A patent/CA2970391A1/en not_active Abandoned
- 2015-11-12 RU RU2017124612A patent/RU2017124612A/ru not_active Application Discontinuation
- 2015-11-12 CN CN201580067628.6A patent/CN106999493A/zh active Pending
- 2015-11-12 JP JP2017531477A patent/JP2017537939A/ja active Pending
- 2015-11-12 AU AU2015360005A patent/AU2015360005A1/en not_active Abandoned
- 2015-11-12 MX MX2017007372A patent/MX2017007372A/es unknown
- 2015-11-12 KR KR1020177018885A patent/KR20170090499A/ko unknown
-
2017
- 2017-04-18 PH PH12017500718A patent/PH12017500718A1/en unknown
- 2017-06-07 IL IL252752A patent/IL252752A0/en unknown
- 2017-06-09 CL CL2017001478A patent/CL2017001478A1/es unknown
- 2017-07-11 ZA ZA2017/04654A patent/ZA201704654B/en unknown
-
2019
- 2019-09-06 US US16/563,018 patent/US20190388423A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017001478A1 (es) | 2018-01-05 |
| SG11201704767YA (en) | 2017-07-28 |
| IL252752A0 (en) | 2017-08-31 |
| UA120108C2 (uk) | 2019-10-10 |
| MX2017007372A (es) | 2017-11-06 |
| RU2017124612A (ru) | 2019-01-14 |
| AU2015360005A1 (en) | 2017-07-27 |
| US10532052B2 (en) | 2020-01-14 |
| US20170319581A1 (en) | 2017-11-09 |
| JP2017537939A (ja) | 2017-12-21 |
| CN106999493A (zh) | 2017-08-01 |
| EP3229806A1 (en) | 2017-10-18 |
| BR112017012136A2 (pt) | 2018-01-02 |
| CA2970391A1 (en) | 2016-06-16 |
| WO2016091346A1 (en) | 2016-06-16 |
| PH12017500718A1 (en) | 2017-10-09 |
| RU2017124612A3 (ru) | 2019-06-05 |
| ZA201704654B (en) | 2019-08-28 |
| US20190388423A1 (en) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6240658B2 (ja) | 抗がん活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体と他の抗腫瘍化合物との組み合わせ | |
| US20190388423A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor | |
| US10231972B2 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative | |
| EP2906294B1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor | |
| CA2935892C (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with gefitinib | |
| KR20160099724A (ko) | 신장 세포 암종 (rcc) 치료를 위해 사용되는 6-옥소-1,6-디히드로-피리다진 유도체 |